



May 21, 2026

Dear Members of the United States Senate:

Consumer Action for a Strong Economy (CASE) writes today on behalf of millions of American consumers, urging lawmakers to oppose any legislative efforts during the upcoming budget reconciliation process to implement a most-favored-nation (MFN) drug pricing model into the United States healthcare system. Government price controls undermine free-market competition, threaten patient access to innovative treatments, and weaken America's leadership in medical innovation.

By linking U.S. drug prices to those set abroad, MFN would effectively import the shortages, access restrictions, and delayed treatments that patients in other countries routinely face. Government-imposed price controls discourage innovation by undermining the incentives that drive pharmaceutical research and development (R&D). Drug development is a high-risk process that requires significant [upfront investment](#), and implementing price controls would destabilize the innovation ecosystem by reducing investment certainty. Rather than making prescriptions more affordable, MFN would distort competition by forcing medicines to be sold well below market prices, ultimately threatening patient access to critical therapies. At the same time, it risks weakening America's leadership in biopharmaceutical innovation—a risk our nation simply cannot afford.

Rather than imposing government price-setting policies that have historically led to shortages, rationing, and reduced patient choice, lawmakers should instead pursue market-oriented reforms that increase competition and promote transparency. For example, policymakers should continue working with the Trump administration to expand direct-to-consumer (DTC) drug sale options, allowing patients to purchase medications closer to the manufacturer's price. Expanding DTC sales would increase transparency, strengthen competition, and help lower costs by reducing the control healthcare middlemen have over the drug pricing system.

American consumers need solutions that lower healthcare costs without jeopardizing access to care or innovation. CASE urges Congress to oppose any legislative efforts to codify MFN price controls, or government-imposed price-setting, and instead continue working with the President to advance market-driven reforms that promote affordability and preserve innovation.

Thank you for your time and consideration on this important issue.

Sincerely,

Consumer Action for a Strong Economy (CASE)